FDA approves once-weekly hemophilia A therapy

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved Sanofi and Sobi’s Altuviiio (efanesoctocog alfa): a first-in-class, high-sustained factor VIII replacement therapy.


EU approves first gene therapy for hemophilia B

By Jonathan Smith

Three months after receiving the US green light, CSL’s candidate Hemgenix has become the first gene therapy to gain EU approval for the treatment of hemophilia B.